Yaky Yanay
2008
In 2008, Yaky Yanay earned a total compensation of $464.7K as Chief Financial Officer at Pluristem Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $28,945 |
|---|---|
| Salary | $168,475 |
| Stock Awards | $245,268 |
| Other | $21,982 |
| Total | $464,670 |
Yanay received $245.3K in stock awards, accounting for 53% of the total pay in 2008.
Yanay also received $28.9K in non-equity incentive plan, $168.5K in salary and $22K in other compensation.
Rankings
In 2008, Yaky Yanay's compensation ranked 6,743rd out of 9,135 executives tracked by ExecPay. In other words, Yanay earned more than 26.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,743 out of 9,135 | 26th |
Division Manufacturing | 2,505 out of 3,436 | 27th |
Major group Chemicals And Allied Products | 565 out of 815 | 31st |
Industry group Drugs | 395 out of 597 | 34th |
Industry Biological Products, Except Diagnostic Substances | 65 out of 118 | 45th |
Source: SEC filing on November 23, 2009.
Yanay's colleagues
We found one more compensation record of an executive who worked with Yaky Yanay at Pluristem Therapeutics in 2008.
2008
Zami Aberman
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019